Ridgeback Capital — 2014 Investments

1 investments dated 2014 · listed companies and verified rows first · show all

Fibrogenfibrogen.com in 𝕏Nov 2014

Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions.

BiotechHealthtechSan Francisco, US

Thomas B. Neff(Executive Officer, Director)Frank H. Valone(Executive Officer)K. Peony Yu(Executive Officer)Pat Cotroneo(Executive Officer)

BoardRory B. Riggs(Director)Kalevi Kurkijarvi(Director)

Co-investorsAvalon BioVentures Scientia Ventures Maverick Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.